StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Aclaris Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aclaris Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$62.06M. For fiscal 2025 it was -$47.11M. The highest annual figure on record is -$4.92M in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.11M–
FY2024Dec 31, 2024-$20.08M–
FY2023Dec 31, 2023-$78.33M–
FY2022Dec 31, 2022-$67.57M–
FY2021Dec 31, 2021-$52.13M–
FY2020Dec 31, 2020-$38.63M–
FY2019Dec 31, 2019-$96.45M–
FY2018Dec 31, 2018-$100.81M–
FY2017Dec 31, 2017-$54.66M–
FY2016Dec 31, 2016-$34.60M–
FY2015Dec 31, 2015-$20.37M–
FY2014Dec 31, 2014-$7.64M–
FY2013Dec 31, 2013-$4.92M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.85M–
Q1 FY2026Mar 31, 2026-$18.15M–
Q4 FY2025Dec 31, 2025-$13.13M–
Q3 FY2025Sep 30, 2025-$10.93M-149.7%
Q2 FY2025Jun 30, 2025-$9.99M–
Q1 FY2025Mar 31, 2025-$13.06M–
Q4 FY2024Dec 31, 2024-$8.94M–
Q3 FY2024Sep 30, 2024$22.00M–
Q2 FY2024Jun 30, 2024-$12.32M–
Q1 FY2024Mar 31, 2024-$20.82M–
Q4 FY2023Dec 31, 2023-$6.76M–
Q3 FY2023Sep 30, 2023-$24.56M–
Q2 FY2023Jun 30, 2023-$20.65M–
Q1 FY2023Mar 31, 2023-$26.35M–
Q4 FY2022Dec 31, 2022-$19.12M–
Q3 FY2022Sep 30, 2022-$7.82M–
Q2 FY2022Jun 30, 2022-$19.67M–
Q1 FY2022Mar 31, 2022-$20.97M–
Q4 FY2021Dec 31, 2021-$17.08M–
Q3 FY2021Sep 30, 2021-$10.61M–
Q2 FY2021Jun 30, 2021-$12.22M–
Q1 FY2021Mar 31, 2021-$12.23M–
Q4 FY2020Dec 31, 2020-$8.86M–
Q3 FY2020Sep 30, 2020-$12.15M–
Q2 FY2020Jun 30, 2020-$10.82M–
Q1 FY2020Mar 31, 2020-$6.81M–
Q4 FY2019Dec 31, 2019-$20.39M–
Q3 FY2019Sep 30, 2019-$23.36M–
Q2 FY2019Jun 30, 2019-$21.38M–
Q1 FY2019Mar 31, 2019-$31.32M–
Q4 FY2018Dec 31, 2018-$27.25M–
Q3 FY2018Sep 30, 2018-$29.86M–
Q2 FY2018Jun 30, 2018-$21.83M–
Q1 FY2018Mar 31, 2018-$21.87M–
Q4 FY2017Dec 31, 2017-$18.21M–
Q3 FY2017Sep 30, 2017-$13.71M–
Q2 FY2017Jun 30, 2017-$10.08M–
Q1 FY2017Mar 31, 2017-$12.66M–
Q4 FY2016Dec 31, 2016-$8.07M–
Q3 FY2016Sep 30, 2016-$9.91M–

More Aclaris Therapeutics figures

See a number that looks wrong?